Funapide - 10mM in DMSO , CAS No.1259933-16-8

CAS: 1259933-16-8 Cat. No.: F656164 Summenformel: C22H14F3NO5 Molekulargewicht: 429.35 EG-Nummer: 810-417-7 PubChem CID: 49836093
Zu bestellen verfügbar
QUALITÄT & REINHEIT 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Größe
Deutschland (EU)
USA*
Preis
Menge
1ml
F656164-1ml
Auf Bestellung · 8–12 Wochen
291,47€
Enter a quantity for the sizes you want to add.

Übersicht

Funapide (TV 45070; XEN402) is a potent Sodium Channel Nav1.7 inhibitor.

Spezifikationen

Spezifikationen & Reinheit
10mM in DMSO
Biochemische und physiologische Mechanismen
Funapide (TV 45070; XEN402) is a potent Sodium Channel Nav1.7 inhibitor.
Storage
Store at -80°C
Verschickt in
Dry ice packs + Cold packs
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Aktionsart
INHIBITOR
Namen und Kennungen
Isomere SMILES
C1[C@]2(C3=CC=CC=C3N(C2=O)CC4=CC=C(O4)C(F)(F)F)C5=CC6=C(C=C5O1)OCO6
PubChem CID
49836093
Molekulargewicht
429.35

Erweiterte Daten

Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Lösungsrechner
Bewertungen

Kundenbewertungen

Application Protocols
  • Verified application data (from Product Data): Not provided.
  • General research-use protocol (tool compound handling; literature-informed, not product-specific):
    • Stock preparation: Dissolve funapide in anhydrous DMSO to 10–50 mM. Filter through 0.22 µm PTFE if needed. Aliquot and store at −80°C to avoid repeated freeze–thaw.
    • In vitro assays (e.g., patch-clamp or fluorescence-based voltage assays):
      • Dilute stock into external solution or assay buffer to the desired concentration range (for tool compounds typically spanning low-nM to low-µM). Maintain constant DMSO across all wells/conditions.
      • Include vehicle controls and known positive/negative controls for assay validation.
      • Equilibrate compounds with cells for a defined pre-incubation (e.g., 5–30 min) before recording; optimize for your system.
    • Data quality:
      • Confirm final compound concentration by preparing gravimetrically validated stocks and tracking dilutions.
      • Assess compound carryover/adsorption by including washout tests and plate-type controls.
  • Note: Adjust steps to your institutional SOPs; for any critical parameters (concentration, incubation time), validate empirically.
Biological Roles
  • Scope: Non-clinical, biochemical/physiological context only (literature). Not for human or veterinary use.
  • Literature overview:
    • Funapide is reported as a small-molecule modulator of voltage-gated sodium channels (NaV), used as a tool compound to interrogate sodium-channel–mediated excitability in excitable cells.
    • Such compounds help delineate roles of specific NaV isoforms (e.g., Nav1.x family) in action potential initiation, propagation, and neuronal signaling.
    • By selectively altering channel gating or conductance, researchers can map downstream effects on neurotransmission, synaptic plasticity, and pain-transduction pathways in cellular and tissue models.
  • Experimental utility:
    • Serves as a benchmark inhibitor/modulator in electrophysiology (patch clamp) and high-content screening to validate assay robustness and dynamic range.
    • Enables structure–activity relationship (SAR) comparisons when profiling novel NaV-targeting chemotypes.
  • Cautionary notes:
    • Confirm isoform selectivity and off-target profile under your assay conditions; sodium-channel pharmacology is sensitive to temperature, holding potential, and use-dependence.
    • Ensure the final DMSO percentage does not perturb membrane properties or channel function; include vehicle controls.
  • Item-specific biological data: Not specified for this item; refer to primary literature and the product CoA for any available characterization.
Buffer Applications
  • Not a buffer component: Funapide is not used to establish or maintain pH. Conventional buffering systems (HEPES, PBS, Tris, MOPS) should be selected based on your biological assay requirements.
  • Practical handling in buffers (general):
    • Prepare concentrated DMSO stock and dilute into the working buffer immediately before use. Target final DMSO ≤0.1–0.5% v/v unless your system tolerates more.
    • To mitigate precipitation in aqueous media, consider:
      • Slow addition of stock to vigorously stirred buffer.
      • Inclusion of 0.01–0.1% non-ionic surfactant (e.g., Tween-20, Pluronic F-68) if compatible.
      • pH optimization within biologically acceptable limits if ionizable groups are present.
    • Filter working solutions (0.22 µm) when compatible with the assay to remove particulates.
  • Item-specific buffer compatibility: Not specified for this item; validate empirically for your application.
Green Alternatives
  • Context: “Green alternatives” generally concerns solvents and reagents. Funapide is a bioactive small molecule tool compound rather than a process reagent; therefore substitution is usually not applicable.
  • If your goal is to reduce environmental impact in studies using funapide as a control compound:
    • Minimize DMSO usage by preparing higher-concentration stocks and using low final assay percentages (≤0.1% v/v when compatible with the biology).
    • Employ micro-scale assay formats (96/384/1536-well) to reduce compound and solvent consumption.
    • Use aqueous buffers with biodegradable surfactants where feasible and validate solubility.
    • Ensure proper waste segregation for halogenated vs non-halogenated streams; many drug-like organics should be collected as hazardous organic waste.
  • Substitution note: There is no “green substitute” for the bioactivity profile of funapide; if a mechanistic control is needed, consider alternative tool compounds with similar target profiles but validate potency, selectivity, and safety characteristics independently (literature-based decision).
Pharmaceutical Uses
  • Formulation role (general research context):
    • Funapide may be used as a reference standard/tool compound in preclinical research to evaluate sodium-channel modulation. It is not supplied for therapeutic or diagnostic use.
    • In formulation method development (non-clinical), typical approaches include solubilization in DMSO/PEG/ethanol co-solvent systems or cyclodextrin inclusion complexes for in vivo exploratory studies; ensure institutional approvals and follow animal welfare regulations when applicable.
  • Pharmacopeial status: Not specified for this item; no pharmacopeial monograph is indicated in the Product Data.
  • Excipient compatibility and stability data: Not specified for this item; assess experimentally.
  • Compliance note: For any GLP/GMP or regulated application, obtain and review full specifications, impurity profile, and stability data from the CoA/Spec Sheet; this catalog item is for research use only.
Physical Properties
  • Item-specific specifications: Not specified for this item; refer to CoA/Spec Sheet.
  • Typical properties for small-molecule ion-channel tool compounds (general/literature guidance; not item specifications):
    • Physical state: often isolated as a solid (free base or salt) with moderate lipophilicity.
    • Aqueous solubility: frequently low at neutral pH; DMSO stocks (10–50 mM) are commonly used for bioassays.
    • pKa/logP: sodium-channel blockers often exhibit basic centers (pKa ~7–10) and logP in the 2–5 range to access the channel pore; verify for funapide via literature before use.
    • UV absorbance: aromatic chromophores typically afford strong UV signals (200–300 nm), enabling HPLC-UV quantification; confirm λmax empirically.
  • Practical lab notes (general):
    • Prepare concentrated DMSO stocks (e.g., 10 mM), then dilute into assay buffer immediately prior to use to minimize precipitation.
    • If form/solubility is uncertain, perform a small-scale solubility screen across DMSO, DMF, ethanol, and aqueous buffers at intended pH.
    • For analytical characterization, reversed-phase HPLC with gradients of water (0.1% formic acid) and acetonitrile is typically effective.
Quality and Grades
  • Grade/purity (from Product Data): Not specified for this item; refer to CoA/Spec Sheet.
  • Interpreting purity and quality for small-molecule tool compounds (general guidance):
    • High chemical purity (typically ≥95% by HPLC/LC-MS) and structural confirmation (NMR/MS) are recommended for quantitative biology.
    • Low residual solvents and well-defined counterion/salt form improve assay reproducibility; verify on the CoA.
    • For screening libraries, batch-to-batch identity is typically controlled by LC-MS and HPLC retention; confirm acceptance criteria on the Spec Sheet.
  • Stabilizers/additives: Not specified for this item; refer to CoA/Spec Sheet.
  • UV/fluorescence background: If using in optical assays, confirm absorbance/fluorescence background of the lot to avoid assay interference.
Reaction and Applications
  • Applicability as a reagent: Funapide is not typically used as a synthetic reagent or solvent. It is primarily a bioactive reference compound in ion-channel research.
  • Research applications (general/literature):
    • Employed as a chemical probe to modulate voltage-gated sodium channels in cellular or electrophysiological systems to dissect channel function and signaling pathways.
    • Useful as a positive control in screening campaigns targeting NaV isoforms; enables benchmarking of assay performance (potency windows, signal-to-background).
  • Practical considerations:
    • Prepare concentrated DMSO stocks (e.g., 10 mM) and aliquot to minimize freeze–thaw.
    • Verify compound identity/purity in the working batch (LC-MS/HPLC) for quantitative pharmacology.
    • Assess potential assay interference (detergent binding, fluorescence/UV interference) before high-throughput use.
  • For chemical synthesis use-cases: Not typically applicable; choose appropriate reagents listed under Synthetic Utility if you require building blocks or catalysts.
Reaction Conditions
  • Not applicable as a reagent: Funapide is not typically employed as a reagent, catalyst, or solvent in synthetic transformations; therefore no standard reaction conditions apply.
  • Analytical preparation (general best practices):
    • Stock solution: Dissolve accurately weighed compound in anhydrous DMSO to a convenient concentration (e.g., 10 mM); vortex and sonicate if needed.
    • Working solutions: Dilute into assay buffer or mobile phase immediately prior to use to mitigate precipitation.
    • Stability checks: Conduct short-term stability in vehicle (room temperature/4°C) and long-term in frozen aliquots; analyze by LC-MS/HPLC.
  • If your workflow requires chemical transformation of the molecule, first obtain structural details (CoA/Spec Sheet) and consult literature for any reported functional group compatibility; no item-specific reactivity data are provided.
Safety and Handling
  • Hazard classification (from Product Data):
    • Signal word: Not specified for this item; refer to SDS.
    • H-statements: Not specified for this item; refer to SDS.
    • GHS classification and pictograms: Not specified for this item; refer to SDS.
  • General laboratory safety guidance (professional best practice; defer to SDS for authoritative details):
    • Handle in a chemical fume hood while wearing appropriate PPE: lab coat, safety glasses, and suitable gloves (e.g., nitrile). Avoid inhalation of dust or aerosols.
    • Prevent skin/eye contact; wash thoroughly after handling. Avoid ingestion and environmental release.
    • Incompatibilities: strong oxidizers and strong acids/bases may degrade typical drug-like organics; segregate accordingly.
    • First aid (overview; consult SDS): in case of skin/eye contact, rinse with water for at least 15 minutes and seek medical attention if irritation persists. If inhaled, move to fresh air; if ingested, seek medical advice.
    • Spill response: absorb small spills with inert material, collect for disposal; ventilate area. Dispose in accordance with institutional and local regulations.
  • Research use only: Not for human or veterinary use. Always consult the Aladdin SDS specific to this SKU prior to work.
Solvent Selection
  • Intended use: Funapide is a bioactive small molecule supplied for research. Solvent selection focuses on preparing analytical standards and assay stocks rather than serving as a reaction solvent.
  • Item-specific solubility: Not specified for this item; refer to CoA/Spec Sheet.
  • Practical selection (general/literature for drug-like solids):
    • Primary stock solvent: DMSO is typically preferred due to high solvating power for lipophilic molecules and compatibility with biological assays at ≤0.1–1% v/v.
    • Co-solvents for method development: DMF, acetonitrile, methanol, or ethanol can aid dissolution; subsequent dilution into aqueous buffers should be slow to minimize precipitation.
    • Buffers: PBS or HBSS with 0.1–1% DMSO and 0.01–0.1% non-ionic surfactant (e.g., Tween-20 or Pluronic F-68) may help maintain solubility for in vitro work.
    • Analytical compatibility: Reversed-phase LC using water (0.1% FA) and acetonitrile/methanol is generally effective; confirm with test injections.
  • Comparison (general):
    • DMSO vs DMF: DMSO is more biocompatible for cellular assays; DMF is useful for dissolution but less favored in biology.
    • Aqueous-only: Often insufficient for hydrophobic drug-like molecules; use co-solvents or pH adjustment when chemically appropriate.
Storage and Reconstitution
  • Storage (from Product Data):
    • Store at −80°C.
    • Shipped with dry ice packs + cold packs to maintain low temperature during transit.
  • Stability notes (general best practices for small-molecule solids/films; verify on CoA for this item):
    • Keep container tightly closed under dry, inert conditions. Protect from light and moisture to prevent degradation.
    • For long-term storage, consider desiccation and headspace purging with inert gas (N2/Ar) if compatible with container system.
  • Reconstitution (general guidance):
    • Bring vial to room temperature in a desiccator before opening to avoid water condensation.
    • Prepare a concentrated stock in anhydrous DMSO (e.g., 10–50 mM). Mix thoroughly; gentle warming (≤40°C) and brief sonication can aid dissolution if permitted by stability.
    • Aliquot stock into low-bind tubes; store at −80°C. Avoid repeated freeze–thaw cycles; thaw on ice and use promptly.
    • Inspect solutions for precipitation or discoloration before use; discard if instability is observed.
  • Item-specific solubility and stability limits: Not specified for this item; refer to CoA/Spec Sheet.
Structure and Identity
  • Item-specific identifiers (from Product Data):
    • SKU: F656164
    • Product name: Funapide
    • CAS: 1259933-16-8
    • PubChem CID: 49836093
    • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Structural description (general/literature):
    • Funapide (also known in literature as a small-molecule voltage-gated sodium channel modulator) is reported as a drug-like, heteroatom-containing aromatic compound typical of ion-channel tool compounds.
    • 2D structural features (literature, qualitative): aromatic ring system(s), amide/urea/tertiary amine-like functionality often present in NaV modulators; overall lipophilic scaffold with polar heteroatoms to engage channel vestibule residues.
  • Notes:
    • Where exact structural line notations (SMILES/InChI) or elemental formula are required for regulatory or analytical work, consult the product CoA/Specification Sheet or authoritative databases using the CAS or CID given above.
Synthetic Utility
  • Not a building block: Funapide is a finished bioactive small molecule and is not typically used as a synthetic intermediate or reagent.
  • If synthetic modification is of interest (general guidance):
    • Derivatization of drug-like scaffolds for SAR can involve amide/urea transformations, heteroaryl substitutions, or side-chain modifications, but specific reactive handles for funapide are not provided in the Product Data.
    • Prior to any derivatization campaign, determine the exact structure (SMILES/InChI) and identify strategic vectors that retain NaV engagement while tuning ADME or selectivity.
  • For preparative chemistry needs: Select dedicated reagents, catalysts, and building blocks from our catalog appropriate to your target synthesis; funapide itself is not recommended as a synthon.
Target Specificity
  • Item-specific target data (from Product Data): Not provided.
  • Policy note: This section reports only product-specific, catalog-verified target attributes (e.g., isoform selectivity, Ki/IC50). As none are supplied in the Product Data, please consult the product CoA/Spec Sheet and primary literature for detailed target profiling under defined assay conditions.

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.